Teleflex’s subsidiary NeoTract has reported positive outcomes from an independent analysis of its UroLift System in UK patients with benign prostatic hyperplasia (BPH).

Conducted by Imperial College Health Partners, the study compared costs and patient outcomes between UroLift and the current standard of care, transurethral resection of the prostate (TURP).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Data revealed significant quality of life benefits with the UroLift System. It was further found that replacing TURP with UroLift can save around £27m in post-surgical complication costs for the National Health Service (NHS).

Unlike TURP, which requires hospitalisation of 2.7 days on average, UroLift System does not require overnight hospitalisation, general anaesthesia or post-operative catheterisation.

NHS Trust Leeds Teaching Hospitals urology consultant Oliver Kayes said: “The data analysis from this study sheds new light on the potential cost savings and improved patient outcomes associated with the prostatic urethral lift treatment.

“The UroLift System offers men a new minimally invasive option that reduces the occurrence of these unpleasant side-effects.”

“Post-surgery complications including urinary tract infections and blood transfusions are expensive complications of TURP and burdensome to men. The UroLift System offers men a new minimally invasive option that reduces the occurrence of these unpleasant side-effects.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

UroLift System is designed for the treatment of lower urinary tract symptoms caused due to BPH.

The system requires a minimally invasive transurethral outpatient procedure, during which patients receive permanent implants to alleviate prostate obstruction and directly open the urethra.

Teleflex Interventional Urology business unit president Dave Amerson said: “We are pleased to see this independent analysis highlighting the economic benefits to the NHS and improved quality of life British men may experience with the UroLift System treatment.”

Currently, the UroLift System is available in the US, Australia, Europe, South Korea, Mexico and Canada.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact